Q-omics provides the consensus-scored MIR4507 profile across patient tissues and cancer cell-line models. MIR4507 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR4507 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MIR4507 RNA expression shows 6,892 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight HNSC, LUAD, and SKCM as cancer lineages where MIR4507 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4507 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4507 survival associations across molecular data types. MIR4507 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4507 RNA expression–survival associations across cancer types. High MIR4507 expression shows unfavorable associations in LUSC, LIHC, LUAD and THCA, but favorable associations in HNSC and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR4507 RNA expression.
This table summarizes MIR4507 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4507. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4507 shows lower tumor expression in COAD and THCA and higher tumor expression in LUAD. The LUAD box plot shows higher MIR4507 RNA expression in tumor versus normal tissue (log2 FC = +0.419, t-test p < 0.001).
This table shows molecular features associated with MIR4507 in patient tissues and cancer cell lines. In patient samples, MIR4507 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
